ECSP20057847A - Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano - Google Patents

Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano

Info

Publication number
ECSP20057847A
ECSP20057847A ECSENADI202057847A ECDI202057847A ECSP20057847A EC SP20057847 A ECSP20057847 A EC SP20057847A EC SENADI202057847 A ECSENADI202057847 A EC SENADI202057847A EC DI202057847 A ECDI202057847 A EC DI202057847A EC SP20057847 A ECSP20057847 A EC SP20057847A
Authority
EC
Ecuador
Prior art keywords
stimulator
cyclopentane
interferon genes
compounds
sting modulators
Prior art date
Application number
ECSENADI202057847A
Other languages
English (en)
Inventor
Martin James Wythes
Ketan S Gajiwala
Indrawan James Mcalpine
Andreas Maderna
Eugene Yuanjin Rui
Andrew Fensome
Mehran Jalaie
Ryan Patman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP20057847A publication Critical patent/ECSP20057847A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Consiste en compuestos de la fórmula general (I), conforme se puede evidenciar en el resumen contenido en la memoria descriptiva, o una sal farmacéuticamente aceptable del mismo, procesos para la preparación de estos compuestos, composiciones que contiene estos compuestos, y los usos de estos compuestos.
ECSENADI202057847A 2018-03-15 2020-09-15 Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano ECSP20057847A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862643467P 2018-03-15 2018-03-15
US201862666204P 2018-05-03 2018-05-03
US201862742532P 2018-10-08 2018-10-08
US201962809990P 2019-02-25 2019-02-25

Publications (1)

Publication Number Publication Date
ECSP20057847A true ECSP20057847A (es) 2021-04-29

Family

ID=66103038

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202057847A ECSP20057847A (es) 2018-03-15 2020-09-15 Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano

Country Status (25)

Country Link
US (4) US10538542B2 (es)
EP (1) EP3765474B1 (es)
JP (1) JP7266942B2 (es)
KR (1) KR20200131878A (es)
CN (1) CN111918871A (es)
AU (1) AU2019234043A1 (es)
BR (1) BR112020018593A2 (es)
CA (1) CA3093631C (es)
CL (1) CL2020002352A1 (es)
CR (1) CR20200382A (es)
DO (1) DOP2020000160A (es)
EC (1) ECSP20057847A (es)
ES (1) ES2923298T3 (es)
IL (1) IL277278A (es)
MA (1) MA52012A (es)
MX (1) MX2020009587A (es)
NI (1) NI202000058A (es)
PE (1) PE20210412A1 (es)
PH (1) PH12020551486A1 (es)
PY (1) PY1919127A (es)
RU (1) RU2020130048A (es)
SG (1) SG11202008102VA (es)
TW (1) TWI741268B (es)
UY (1) UY38145A (es)
WO (1) WO2019175776A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
TWI741268B (zh) * 2018-03-15 2021-10-01 美商輝瑞股份有限公司 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
MX2022003633A (es) * 2019-09-25 2022-04-19 Pfizer Moduladores poliheterociclicos de sting (estimulador de genes de interferon).
EP4134098A4 (en) 2020-04-10 2024-05-15 ONO Pharmaceutical Co., Ltd. Method of cancer therapy
JP2023553069A (ja) * 2020-12-08 2023-12-20 エフ． ホフマン－ラ ロシュ アーゲー ホスホロジチオエートオリゴヌクレオチドの新規合成
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI741268B (zh) * 2018-03-15 2021-10-01 美商輝瑞股份有限公司 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑

Also Published As

Publication number Publication date
US10968242B2 (en) 2021-04-06
EP3765474B1 (en) 2022-06-15
US10538542B2 (en) 2020-01-21
TWI741268B (zh) 2021-10-01
RU2020130048A3 (es) 2022-04-15
US20230382932A1 (en) 2023-11-30
JP2021518335A (ja) 2021-08-02
US20200102334A1 (en) 2020-04-02
MA52012A (fr) 2021-01-20
AU2019234043A1 (en) 2020-09-17
PY1919127A (es) 2020-08-26
EP3765474A1 (en) 2021-01-20
PE20210412A1 (es) 2021-03-04
KR20200131878A (ko) 2020-11-24
UY38145A (es) 2019-10-31
TW201945036A (zh) 2019-12-01
RU2020130048A (ru) 2022-04-15
CL2020002352A1 (es) 2020-12-18
US20190284216A1 (en) 2019-09-19
CN111918871A (zh) 2020-11-10
NI202000058A (es) 2021-01-08
US20210230196A1 (en) 2021-07-29
JP7266942B2 (ja) 2023-05-01
CR20200382A (es) 2020-12-10
PH12020551486A1 (en) 2021-08-23
ES2923298T3 (es) 2022-09-26
CA3093631C (en) 2023-01-24
MX2020009587A (es) 2020-10-05
DOP2020000160A (es) 2020-09-30
BR112020018593A2 (pt) 2020-12-29
WO2019175776A1 (en) 2019-09-19
SG11202008102VA (en) 2020-09-29
CA3093631A1 (en) 2019-09-19
IL277278A (en) 2020-10-29

Similar Documents

Publication Publication Date Title
ECSP20057847A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CL2020000299A1 (es) Compuestos, composiciones y métodos.
DOP2020000050A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
DOP2022000066A (es) Moduladores de sting (estimulador de genes de interferón)
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
MX2021009673A (es) Moduladores de ror-gamma.
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
CO2018002060A2 (es) Compuestos farmacéuticos
UY36285A (es) Compuestos que inhiben la proteína mcl-1
CO2017012268A2 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
UY37098A (es) Moduladores de ror-gamma
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CL2019001106A1 (es) Composición para aliviar o tratar el dolor.
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
AR122310A1 (es) Moduladores de sting (estimulador de genes de interferón)
EA201892095A1 (ru) Циклические динуклеотидные соединения и способы их применения